@article{article, title  = {{Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party}},

 publisher = {{Springer Science and Business Media LLC}},

 url = {{https://doi.org/10.1038/s41409-026-02805-4 }},

 year = {{2026}},

 month = {{3}},

 author = {{Bug G and Labopin M and Byrne JL and Mielke S and Orchard K and Paneesha S and Potter V and Blaise D and Besley C and Snowden JA and Yakoub-Agha I et al}},

 doi = {{10.1038/s41409-026-02805-4}},

 journal = {{Bone Marrow Transplantation}},

 note = {{Accessed on 2026/03/17}}}